David Cordas dos Santos: Nonrelapse mortality after CAR-T cell treatment
David Cordas dos Santos, PostDoc at Dana-Farber Cancer Institute, made the following post on X:
“Check out our new study in Nature Medicine looking at nonrelapse mortality after CAR-T cell treatment with Tobias Tix and Kai Rejeski.
Including 46 studies with 7,604 patients, we found an overall NRM of 6.8% at a follow-up time of 13.4 months, which varied between disease entities (MCL>MM>LBCL>IL) and CAR-T products.
Over 50% of nonrelapse-related deaths were due to infections followed by secondary malignancies (7.8%) and cardiovascular/respiratory events (7.3%).
Take home messages:
- Infection prevention an management is paramount in patients untergoing CAR-T treatment
- NRM may be one of the factors to consider for selection and counseling of patients planned for CAR-T therapy.
That was such a fast-paced project which wouldn’t have been possible without the amazing Tobias Tix and the amazing
Kai Rejeski!
Truly, a science dream team!
Very grateful for all the co-authors: Eddie Cliff, JB Alberge, Irene Ghobrial, Sebastian Theurich, Michael von Bergwelt, Mari Subklewe, Roni Shouval, Miguel Perales.
And an amazing collaboration between institutions Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, LMU University Hospital Munich.”
Source: David Cordas dos Santos/X